BioXcel Therapeutics Inc (NASDAQ:BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype, the most common form of the disease.
As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS of 15.5 months and a 12-month survival rate of 59%.
Also Read: Schizophrenia Player BioXcel’s Drug Faces Funding Headwinds, Analyst Downgrades Stock.
The company reported a RECIST partial response rate of 28% with a median duration of response of 19 months. This is in contrast to a RECIST response rate of 5% with a median duration of response of 16.8 months from the KEYNOTE-199 trial of pembrolizumab monotherapy in a similar patient population.
The company continues to evaluate strategic options for OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A.
OnkosXcel Therapeutics is a wholly owned subsidiary of BioXcel Therapeutics, Inc., focused on developing medicines in oncology utilizing artificial intelligence. The subsidiary was formed in 2022 to develop BXCL701.
BXCL701 is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment.
Price Action: BTAI shares are down 6.78% at $4.51 on the last check Wednesday.
